Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
HIV Protease Inhibitor
Saquinavir is a protease inhibitor. Proteases are enzymes that cleave protein molecules into smaller fragments. Saquinavir inhibits both HIV-1 and HIV-2 proteases.- Ernawati Arifin Giri-Rachman, .et al. , ACS Synth Biol, 2024, Feb 16; 13(2): 509-520 PMID: 38316139
- Reiko Watanabe, .et al. , J Med Chem, 2021, Mar 11;64(5):2725-2738 PMID: 33619967
-
HIV-1 protease inhibitor
Nelfinavir is a potent and orally bioavailable human immunodeficiency virus HIV-1 protease inhibitor (Ki=2 nM) and is widely prescribed in combination with HIV reverse transcriptase inhibitors for the treatment of HIV infection.- Joanna Ireland, .et al. , Front Microbiol, 2024, Mar 20:15:1385775 PMID: 38572241
- Reiko Watanabe, .et al. , J Med Chem, 2021, Mar 11;64(5):2725-2738 PMID: 33619967
- Yang PM, .et al. , Am J Cancer Res, 2019, Oct 1;9(10):2120-2139 PMID: 31720078
-
HIV-1 attachment inhibitor
BMS-663068 is an HIV-1 attachment inhibitor in development for the treatment of HIV-1 infection.- Min Li, .et al. , J Infect Dis, 2025, Jul 16:jiaf373
- Min Li, .et al. , Nat Commun, 2020, 11: 4051 PMID: 32792548
-
HIV-1 maturation inhibitor
Bevirimat (MPC-4326, PA-457, YK-FH312) is a first-in-class HIV-1 maturation inhibitor that demonstrates high potency in cell culture and has shown clinical efficacy in HIV-1-infected patients.- Mingzhang Wang, .et al. , Nat Commun, 2017, 8: 1779 PMID: 29176596
-
HIV Protease inhibitor
Atazanavir is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). -
HIV Protease inhibitor
Atazanavir is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). -
HIV Protease inhibitor
Ritonavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease.Ritonavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. -
human immunodeficiency virus protease inhibitor
Des(benzylpyridyl) Atazanavir is a metabolite of Atazanavir, a human immunodeficiency virus protease inhibitor. -
HIV Protease Inhibitor
Cytochalasin A is a cell-permeable fungal toxin that is an oxidized derivative of cytochalasin B. Cytochalasin A is an inhibitor of HIV-1 protease (IC50=3 μM) and inhibits actin polymerization and interferes with microtubule assembly by reacting with sulfhydryl groups. Antibiotic and fungicidal activitives. -
HIV Protease Inhibitor
Palinavir is a potent inhibitor of HIV-1 and HIV-2 proteases, exhibiting an IC50 range of 0.5-30 nM. It demonstrates significant antiviral activity, making it valuable for research focused on HIV treatment strategies and drug development. Palinavir's mechanism of action targets the viral protease enzyme, disrupting the replication cycle of the virus and providing insights into HIV pathogenesis and therapeutic interventions. -
HIV Protease Inhibitor
L-689502 is a potent HIV protease inhibitor with an IC50 of 1 nM. This compound effectively disrupts the proteolytic activity of HIV-1 protease, thereby inhibiting viral replication. L-689502 is valuable for research into antiretroviral therapies and mechanisms of HIV resistance. -
HIV protease Inhibitor
Telinavir is a potent and selective inhibitor of HIV protease. It effectively inhibits various strains of HIV-1, HIV-2, and simian immunodeficiency virus at EC50 values of 26 ng/mL (43 nM). With a high degree of protein binding in human plasma and minimal partitioning into erythrocytes, Telinavir serves as a valuable tool in HIV research and therapeutic development. -
HIV protease inhibitor
SB 204144 is a potent inhibitor of HIV protease, disrupting the proteolytic processing of viral polyproteins and hindering the maturation of infectious HIV particles. This compound is valuable for research on HIV pathogenesis and immune system diseases, enabling studies on antiviral effects and the development of new therapeutic strategies against HIV. Its application in virology underlines its relevance in understanding and combating HIV infection. -
HIV Protease Inhibitor
DMP-851 is a potent cyclic urea inhibitor of HIV protease, exhibiting a Ki of 0.021 nM. It demonstrates significant antiviral activity against both laboratory strains of HIV-1 and HIV-2, as well as primary clinical isolates that are resistant to Zidovudine. This compound serves as an important tool for research into HIV treatment and resistance mechanisms. -
HIV Protease Inhibitor
BILA 1906 BS is a potent HIV protease inhibitor that disrupts HIV-1 replication by inhibiting the protease-mediated cleavage of Gag and Gag-Pol polyprotein precursors during virion maturation. This compound effectively blocks the maturation of p24 proteins in wild-type HIV-1, thereby impairing polyprotein processing and viral maturation. BILA 1906 BS is valuable for research focused on human immunodeficiency virus type 1 (HIV-1) infection and its associated cellular mechanisms. -
HIV Protease Inhibitor
JE-2147 is a potent dipeptide inhibitor of HIV protease, exhibiting a Ki value of 0.33 nM for HIV-1 protease. This compound demonstrates effective antiviral activity against a broad range of HIV strains, including HIV-1, HIV-2, simian immunodeficiency virus, and various clinical isolates of HIV-1 in vitro. JE-2147 serves as a valuable tool for research into HIV protease inhibition and the development of antiretroviral therapies. -
HIV Protease Inhibitor
CGP 53820 is a potent inhibitor of HIV protease, demonstrating Ki values of 9 nM for HIV-1 protease and 53 nM for HIV-2 protease. This compound effectively disrupts the enzymatic activity critical for the replication of HIV, making it a valuable tool in AIDS research and the study of antiretroviral therapies. Its specificity and efficacy support investigations into HIV resistance and the development of novel therapeutic strategies. -
HIV Protease Inhibitor
P-1946 is a potent HIV protease inhibitor demonstrated to have a human HIV-1 protease Ki of 2.600 nM. It exhibits strong and selective in vitro antiviral activity, remaining effective against HIV isolates that have developed resistance to existing protease inhibitors. P-1946 is suitable for research applications focused on human immunodeficiency virus type 1 (HIV-1) infection. -
HIV Protease Inhibitor
BMS 186318 is a potent HIV protease inhibitor that plays a critical role in blocking viral replication by interfering with the proteolytic processing of viral polyproteins. This compound demonstrates enhanced anti-HIV efficacy when used in conjunction with reverse transcriptase inhibitors and additional protease inhibitors. BMS 186318 is ideal for applications in antiviral research, contributing to the development of effective therapeutic strategies against HIV. -
HIV Protease Inhibitor
MK-8718 is a potent and orally bioavailable HIV protease inhibitor that features a morpholine aspartate binding group. This compound effectively inhibits the activity of HIV protease, making it a valuable tool for studying HIV infection and antiretroviral therapy mechanisms. Its application in research may enhance the understanding of HIV replication and contribute to the development of novel therapeutic strategies. -
HIV Protease Inhibitor
PAC-Phe-Val is a potent inhibitor of HIV-1 protease, exhibiting an IC50 value of 33.10 nM. It establishes stable interactions with key active site residues, which enhances its inhibitory efficacy. This compound is suitable for research applications focused on HIV/AIDS and provides significant potential for therapeutic development in this area. -
HIV protease inhibitor
Brecanavir is a potent inhibitor of HIV protease, a crucial enzyme in the HIV life cycle. By inhibiting this enzyme, Brecanavir effectively reduces viral replication, making it a valuable compound in HIV research and therapeutic development. Its potential applications include studying drug resistance mechanisms and exploring combination therapies for enhanced antiviral efficacy. -
HIV Protease Inhibitor
Isoescin IA is a triterpenoid saponin derived from the seeds of Aesculus chinensis, functioning as an HIV protease inhibitor. This compound exhibits significant anti-HIV-1 protease activity, making it a valuable tool for research aimed at understanding HIV replication and potential therapeutic strategies. Its selective inhibition of the protease can aid in the investigation of antiviral mechanisms and drug development in the field of HIV research. -
HIV Protease Inhibitor
Ganodermanondiol is an HIV protease inhibitor derived from Ganoderma lucidum. It demonstrates significant anti-HIV-1 protease activity, with an IC50 of 90 μM, making it a valuable compound for antiviral research. Additionally, Ganodermanondiol exhibits strong cytoprotective effects against tert-butyl hydroperoxide-induced hepatotoxicity and showcases anticomplement activity against the classical pathway of the complement system, with an IC50 of 41.7 μM. This compound is relevant for studies focused on hepatoprotection and immune modulation. -
HIV Protease Inhibitor
HIV-IN-11 is a potent HIV protease inhibitor that disrupts the activity of HIV-1 protease through competitive inhibition, with a Ki of 0.049 nM. This compound effectively inhibits the replication of HIV(IIIb)-infected MT4 lymphocytes at concentrations of 25.0-50.0 nM. Demonstrating a longer half-life compared to indinavir sulfate in animal models, HIV-IN-11 represents a promising candidate for second-generation HIV treatment research. -
HIV Protease Inhibitor
DMP 323 is a potent, nonpeptide cyclic urea inhibitor of HIV protease, targeting both HIV-1 and HIV-2. It functions as a competitive inhibitor by blocking the cleavage of peptide substrates and the HIV-1 gag polyprotein, demonstrating robust antiviral activity. DMP 323 exhibits comparable efficacy to leading HIV protease inhibitors while remaining effective in human plasma or serum, indicating low affinity for plasma proteins. Additionally, it shows minimal inhibition of mammalian proteases at higher concentrations, underscoring its selectivity for HIV protease. -
HIV Protease Inhibitor
AQ148 is a selective HIV-1 protease inhibitor with a Ki value of 137 nM. It demonstrates significant inhibitory activity against aspartic proteases from HIV-1 (IC50 = 1.5 μM), HIV-2 (IC50 = 3.4 μM), and simian immunodeficiency virus (SIV) (IC50 = 5 μM). This compound is useful for research applications focused on HIV pathogenesis and the development of antiviral therapies. -
HIV Protease Inhibitor
20(21)-Dehydrolucidenic acid A is a triterpenoid derived from the fruiting body of Ganoderma sinense, primarily targeting HIV protease. This compound exhibits modest inhibitory activity against HIV-1 protease, making it a valuable tool in the study of HIV pathogenesis and in the development of antiviral strategies. Its unique structure offers potential insights into therapeutic applications for HIV treatment. -
HIV Protease Inhibitor
U-85548E is an HIV protease inhibitor that demonstrates nanomolar affinity for the HIV-1 aspartic protease. This compound has been developed through investigations into its structure-activity relationships, proving effective against both HIV-1 and HIV-2 proteases. Its binding interactions have been characterized using X-ray crystallography and molecular modeling, making it a valuable tool for research in HIV drug development and mechanistic studies of protease inhibition. -
HIV Protease Inhibitor
Kynostatin 272 is a potent inhibitor of the HIV protease, targeting the enzyme's active site by mimicking the substrate transition state. This mechanism effectively disrupts a critical stage in the replication cycle of the HIV virus. Kynostatin 272 serves as a valuable tool in HIV research, aiding in the development of therapeutic strategies for managing HIV and AIDS. -
HIV Protease Inhibitor
Stercobilin hydrochloride (mixture of isomers) serves as an HIV protease inhibitor, exhibiting a Ki value of 4 μM. This bile pigment, derived from gut bacteria metabolism, can promote pro-inflammatory responses in mouse macrophage RAW264 cells, including the upregulation of cytokines such as TNF-α and IL-1β. Applications of Stercobilin hydrochloride extend to the investigation of inflammatory processes and viral infections. -
HIV Protease Inhibitor
GS-9770 is an orally active inhibitor specifically targeting HIV protease, with a Ki of 0.16 nM. It demonstrates potent antiviral activity against both HIV-1 and HIV-2 strains, showing EC50 values ranging from 1.9 to 26 nM. In addition to its efficacy, GS-9770 is metabolically stable in human liver microsomes and exhibits favorable pharmacokinetic properties in Sprague Dawley rats, making it a valuable tool for research in HIV treatment. -
HIV Protease Inhibitor
L 756423 is a potent inhibitor of HIV protease, targeting the enzyme crucial for the maturation of infectious HIV particles. This compound exhibits significant antiviral activity, making it a valuable tool for research into HIV infection and the development of therapeutic strategies. Its effective inhibition of protease could contribute to understanding HIV lifecycle and resistance mechanisms. -
HIV Protease Inhibitor
R-87366 is a water-soluble inhibitor of HIV protease, demonstrating potent inhibition with a Ki value of 11 nM. This compound is instrumental in the study of human immunodeficiency virus (HIV) mechanisms and provides valuable insights for the development of antiviral therapies. R-87366 serves as a key reagent for research focused on combating HIV infections. -
HIV Protease Inhibitor
Lopinavir Metabolite M-1 is a potent HIV protease inhibitor with a Ki of 0.7 pM. This active metabolite exhibits significant antiviral activity in vitro, making it valuable for research on HIV treatment and drug resistance mechanisms. Its efficacy in inhibiting HIV replication underlines its relevance in antiviral studies and therapeutic development. -
HIV Protease Inhibitor
HIV protease-IN-1 is a potent non-peptidic inhibitor of HIV protease, designed to interfere with the viral life cycle. Its primary mechanism involves the inhibition of HIV protease, which is essential for the processing of viral polyproteins into functional proteins. This compound holds significant potential for research applications in the development of therapeutic strategies against AIDS and HIV-related pathologies. -
HIV Protease Inhibitor
A-77003 is a potent HIV protease inhibitor, demonstrating an IC50 range of 0.1 to 0.2 μg/ml against both HIV-1 and HIV-2 proteases. This compound exhibits significant antiretroviral activity while maintaining low cytotoxicity in vitro, making it suitable for research applications focused on HIV treatment and therapeutic development. -
HIV Protease Inhibitor
Ro 31-8588 is a potent HIV protease inhibitor, exhibiting a Ki of 0.3 nM. This compound is essential for studying the role of HIV protease in viral replication and can be utilized in research focused on AIDS treatment and potential therapeutic strategies. Its high affinity makes it a valuable tool for investigating the mechanistic aspects of HIV inhibition. -
HIV Protease Inhibitor
2α,19α-Dihydroxy-3-oxo-urs-12-en-28-oic acid is identified as a potent inhibitor of HIV protease, exhibiting significant antiviral activity. Additionally, this compound inhibits the activation of Epstein-Barr virus early antigen (EBV-EA), demonstrating its utility in virology research. Furthermore, it displays inhibitory effects on nitric oxide production in lipopolysaccharide-activated RAW 264.7 cells, highlighting its potential applications in immunology and inflammation studies. -
HIV protease inhibitor
Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. -
HIV-1 RT inhibitor
Trovirdine inhibits HIV-1 RT with an IC50 of 7 nM when employing heteropolymeric primer/template (oligo-DNA/ribosomal RNA)and dGTP as substrate. -
HIV Entry Inhibitor
BMS-806, also known as BMS-378806 , is a type of medicine called an entry inhibitor. Entry inhibitors work by blocking HIV from entering human cells. BMS-378806 (BMS-806) is a small molecule that blocks the binding of host-cell CD4 with viral gp120 protein and therefore inhibits the first steps of HIV-1 infection. -
HIV Protease Inhibitor
Saquinavir mesylate is an HIV Protease Inhibitor used in antiretroviral therapy. -
HIV protease inhibitor
Darunavir Ethanolate (Prezista) is an HIV protease inhibitor. -
HIV protease inhibitor
Nelfinavir Mesylate is a potent HIV protease inhibitor with Ki of 2 nM.
